Comparative Pharmacology
Head-to-head clinical analysis: LUTREPULSE KIT versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUTREPULSE KIT versus VANTAS.
LUTREPULSE KIT vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUTREPULSE (gonadorelin acetate) is a synthetic decapeptide analog of endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on the anterior pituitary gonadotroph cells, stimulating synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, LH stimulates Leydig cells to produce testosterone; in females, LH triggers ovulation and FSH stimulates follicular development.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
5 mcg subcutaneously every 90 minutes via pulsatile pump.
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
3 hours (initial phase), terminal elimination half-life 10-12 hours; clinically, steady-state reached within 2 days.
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Renal: 10% unchanged; hepatic metabolism, metabolites primarily excreted in bile (70%) and feces.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist